



Suppl. Fig. 5: Flow chart mapping the workflow from histopathological assessment of ependymoma into the use of CORE tests (immunohistochemistry (IHC) and DNA methylation array (MA)) as part of the existing integrated diagnosis of ependymoma outlined in the WHO CNS5, and the inclusion of CORE Plus tests (molecular inversion probe array (MIP) or RNA-next generation sequencing (NGS)) where necessary to assess prognostic copy number information or to determine novel fusion events. We recommend both IHC guided by tumour location and MA as core tests, as these combined allow both diagnostic and prognostic biomarker assessments. Where MA is unavailable limited diagnostic information can be obtained from IHC alone. DNA methylation array classifier scores denoted as  $<$  or  $\geq 0.9$ .